The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20.

Authors

P A Cassier¹, A Floquet, N Penel, O Derbel, B Bui N'guyen, J-P Guastalla, D Pissaloux, I Treilleux, C E Saba, J-Y Blay, I Ray-Coquard

Affiliation

¹ Department of Medical Oncology, Centre Léon Bérard, Lyon.

PMID: 24651409
DOI: 10.1093/annonc/mdu045

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase II as Topic
Female
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylase Inhibitors / therapeutic use*
Humans
Hydroxamic Acids / pharmacology
Hydroxamic Acids / therapeutic use*
Indoles / pharmacology
Indoles / therapeutic use*
Middle Aged
Ovarian Neoplasms / drug therapy*
Panobinostat
Sex Cord-Gonadal Stromal Tumors / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents
Histone Deacetylase Inhibitors
Hydroxamic Acids
Indoles
Panobinostat